Sarcoma Clinical Trials & Research For Children

Through clinical trials, our medical experts evaluate the safety and effectiveness of new therapies and diagnostic tools. Clinical trials can also help our doctors compare the effectiveness of different aspects of your child’s care, or determine the causes of sarcomas.

If your child is eligible to participate in a clinical trial, he or she may have access to new therapies that are not yet available elsewhere. Our clinical research team is highly experienced in selecting children who are most likely to benefit from a particular investigational therapy. They can guide you through the process of choosing the most appropriate clinical trial for your child’s needs.

Learn more about Memorial Sloan Kettering’s current clinical trials for pediatric sarcomas.

and/or
Reset
13 Clinical Trials found
A Phase 1 Study of Avutometinib, a Dual Inhibitor of MEK and RAF, for Children and Young Adults With Advanced Solid Tumors
Researchers want to find the best dose of avutometinib to treat children and young adults with advanced solid tumors. The people in this study have cancers that have spread or come back after treatment. In addition, their cancers have a mutation (change or variant) in a protein family called MAPK. These proteins tell cancer cells to grow.
New York City
A Phase 1 Study of Lurbinectedin in Children With Solid Tumors
In this study, researchers are assessing the safety of the drug lurbinectedin in young people with solid tumors. In the first part, they will find the highest dose of lurbinectedin to use safely in children with solid tumors. If your child joins, this is the part of the study they will be in.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of TORL-1-23 in People With Advanced Solid Tumors
Researchers want to find the best dose of TORL-1-23 to use in people with advanced solid tumors. The people in this study have solid tumors that have spread and cannot be successfully treated with standard therapies.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of Afamitresgene Autoleucel SPEAR T Cell Therapy in Children and Young Adults With Solid Tumors
Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
New York City
A Phase 2-3 Study Assessing the Addition of Cabozantinib to Chemotherapy in People With Newly Diagnosed Osteosarcoma
Researchers want to see if adding cabozantinib to standard chemotherapy works better than chemotherapy alone for osteosarcoma. The people in this study include children, adolescents, and young adults with osteosarcoma that has not yet been treated.
New York City
A Phase I Study of Codrituzumab in Children and Young Adults with Recurrent or Persistent Solid Tumors
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
New York City
A Phase II Study of ASTX727 in People with Malignant Peripheral Nerve Sheath Tumors
This study is assessing the safety and effectiveness of ASTX727 in people who have malignant peripheral nerve sheath tumors (MPNST) with a mutation in a gene complex called PRC2 (EED or SUZ12). ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PRC2 complex genetic mutation and disrupt the cells' ability to survive and grow.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase II Study of Pembrolizumab Immunotherapy plus Local Chemotherapy using Isolated Limb Infusion for Patients with Advanced Sarcoma in the Arm or Leg
Isolated limb infusion (ILI) is a way to give anticancer drugs directly into an arm or leg to treat a sarcoma. However, despite this treatment, sometimes the cancer still spreads to other parts of the body. In this study, researchers want to see if adding the immunotherapy drug pembrolizumab to ILI treatment with the chemotherapy drugs melphalan and dactinomycin can help prevent the spread of cancer and increase the effectiveness of the ILI treatment in people with advanced sarcoma.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase III Study Comparing Two Surgery Methods to Treat Cancer in the Lung in Patients with Bone Cancer
The purpose of this study is to compare two different approaches to surgery for children and adults with osteosarcoma (bone cancer) that has spread (metastasized) to the lungs. Participants will be randomly assigned to one of two techniques:
New York City